NEOGENOMICS INC (NEO) Stock Price & Overview
NASDAQ:NEO • US64049M2098
Current stock price
The current stock price of NEO is 7.96 USD. Today NEO is down by -2.69%. In the past month the price decreased by -18.28%. In the past year, price decreased by -17.04%.
NEO Key Statistics
- Market Cap
- 1.033B
- P/E
- 66.33
- Fwd P/E
- 47.63
- EPS (TTM)
- 0.12
- Dividend Yield
- N/A
NEO Stock Performance
NEO Stock Chart
NEO Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to NEO. When comparing the yearly performance of all stocks, NEO is a bad performer in the overall market: 85.71% of all stocks are doing better.
NEO Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to NEO. The financial health of NEO is average, but there are quite some concerns on its profitability.
NEO Earnings
On February 17, 2026 NEO reported an EPS of 0.06 and a revenue of 190.17M. The company beat EPS expectations (53.54% surprise) and beat revenue expectations (0.13% surprise).
NEO Forecast & Estimates
18 analysts have analysed NEO and the average price target is 14.11 USD. This implies a price increase of 77.26% is expected in the next year compared to the current price of 7.96.
For the next year, analysts expect an EPS growth of 39.26% and a revenue growth 9.85% for NEO
NEO Groups
Sector & Classification
NEO Financial Highlights
Over the last trailing twelve months NEO reported a non-GAAP Earnings per Share(EPS) of 0.12. The EPS increased by 20% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.94% | ||
| ROE | -12.91% | ||
| Debt/Equity | 0.41 |
NEO Ownership
NEO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 9.86 | 91.421B | ||
| CI | THE CIGNA GROUP | 8.41 | 69.722B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 98.65 | 28.394B | ||
| LH | LABCORP HOLDINGS INC | 14.4 | 21.761B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.18 | 21.332B | ||
| GH | GUARDANT HEALTH INC | N/A | 11.685B | ||
| DVA | DAVITA INC | 10.56 | 10.004B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 29.72 | 8.514B | ||
| HIMS | HIMS & HERS HEALTH INC | 40.32 | 5.507B | ||
| CHE | CHEMED CORP | 15.59 | 5.299B | ||
| RDNT | RADNET INC | 77.29 | 4.848B | ||
| OPCH | OPTION CARE HEALTH INC | 14.76 | 4.557B | ||
| HNGE | HINGE HEALTH INC-A | 22.01 | 3.504B |
Related stock screener links
View all stocks in the Health Care Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NEO
Company Profile
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,500 full-time employees. The company went IPO on 2012-12-10. The firm offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. The company operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
Company Info
IPO: 2012-12-10
NEOGENOMICS INC
9490 Neogenomics Way
Fort Myers FLORIDA 33913 US
CEO: Douglas M. VanOort
Employees: 2200
Phone: 12397680600
NEOGENOMICS INC / NEO FAQ
What does NEO do?
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,500 full-time employees. The company went IPO on 2012-12-10. The firm offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. The company operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
What is the current price of NEO stock?
The current stock price of NEO is 7.96 USD. The price decreased by -2.69% in the last trading session.
Does NEOGENOMICS INC pay dividends?
NEO does not pay a dividend.
How is the ChartMill rating for NEOGENOMICS INC?
NEO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Is NEOGENOMICS INC (NEO) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NEO.
Can you provide the growth outlook for NEOGENOMICS INC?
The Revenue of NEOGENOMICS INC (NEO) is expected to grow by 9.85% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the ownership details for NEO stock?
You can find the ownership structure of NEOGENOMICS INC (NEO) on the Ownership tab.